Last reviewed · How we verify
zevor-cel
At a glance
| Generic name | zevor-cel |
|---|---|
| Also known as | CAR-BCMA T Cell Infusion |
| Sponsor | CARsgen Therapeutics Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zevor-cel CI brief — competitive landscape report
- zevor-cel updates RSS · CI watch RSS
- CARsgen Therapeutics Co., Ltd. portfolio CI